Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104


Synergy of brief activation of CD8 T-cells in the presence of IL-12 and adoptive transfer into lymphopenic hosts promotes tumor clearance and anti-tumor memory.

Díaz-Montero CM, Naga O, Zidan AA, Salem ML, Pallin M, Parmigiani A, Walker G, Wieder E, Komanduri K, Cole DJ, Montero AJ, Lichtenheld MG.

Am J Cancer Res. 2011 Aug 30;1(7):882-96.


Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model.

He H, Wisner P, Yang G, Hu HM, Haley D, Miller W, O'Hara A, Alvord WG, Clegg CH, Fox BA, Urba WJ, Walker EB.

J Transl Med. 2006 Jun 13;4:24.


Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts.

Kaiser AD, Gadiot J, Guislain A, Blank CU.

Cancer Immunol Immunother. 2013 Mar;62(3):503-15. doi: 10.1007/s00262-012-1350-1. Epub 2012 Sep 23.


IL-15 signaling promotes adoptive effector T-cell survival and memory formation in irradiation-induced lymphopenia.

Xu A, Bhanumathy KK, Wu J, Ye Z, Freywald A, Leary SC, Li R, Xiang J.

Cell Biosci. 2016 May 6;6:30. doi: 10.1186/s13578-016-0098-2. eCollection 2016.


Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.

Rubinstein MP, Cloud CA, Garrett TE, Moore CJ, Schwartz KM, Johnson CB, Craig DH, Salem ML, Paulos CM, Cole DJ.

J Am Coll Surg. 2012 Apr;214(4):700-7; discussion 707-8. doi: 10.1016/j.jamcollsurg.2011.12.034. Epub 2012 Feb 22.


Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction.

Nechushtan H, Pham D, Zhang Y, Morgensztern D, Yi KH, Shin SU, Federoff HJ, Bowers WJ, Tolba KA, Rosenblatt JD.

Cancer Immunol Immunother. 2008 May;57(5):663-75. Epub 2007 Oct 19.


Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.

Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, Restifo NP, Allison JP.

J Exp Med. 2010 Mar 15;207(3):637-50. doi: 10.1084/jem.20091918. Epub 2010 Feb 15.


Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.

Contreras A, Sen S, Tatar AJ, Mahvi DA, Meyers JV, Srinand P, Suresh M, Cho CS.

Cancer Immunol Immunother. 2016 May;65(5):601-11. doi: 10.1007/s00262-016-1823-8. Epub 2016 Mar 24.


Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.

Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, Farrar EA, Bhatia S, Sabath DE, Cao J, Li Y, Yee C.

Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):4592-7. doi: 10.1073/pnas.1113748109. Epub 2012 Mar 5.


The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans.

Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, Aghamolla T, Alvarez-Downing MM, Lee CC, Singh S, Li T, Dudley ME, Restifo NP, Rosenberg SA, Kammula US.

Sci Transl Med. 2012 Aug 29;4(149):149ra120. doi: 10.1126/scitranslmed.3004306.


CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.

Hervas-Stubbs S, Mancheño U, Riezu-Boj JI, Larraga A, Ochoa MC, Alignani D, Alfaro C, Morales-Kastresana A, Gonzalez I, Larrea E, Pircher H, Le Bon A, Lopez-Picazo JM, Martín-Algarra S, Prieto J, Melero I.

J Immunol. 2012 Oct 1;189(7):3299-310. Epub 2012 Aug 27.


Self-specific CD8+ T cells maintain a semi-naive state following lymphopenia-induced proliferation.

Johnson LD, Jameson SC.

J Immunol. 2010 May 15;184(10):5604-11. doi: 10.4049/jimmunol.1000109. Epub 2010 Apr 14.


Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.

Wu F, Zhang W, Shao H, Bo H, Shen H, Li J, Liu Y, Wang T, Ma W, Huang S.

Cancer Lett. 2013 Oct 10;339(2):195-207. doi: 10.1016/j.canlet.2013.06.009. Epub 2013 Jun 18.


Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.

Roychowdhury S, May KF Jr, Tzou KS, Lin T, Bhatt D, Freud AG, Guimond M, Ferketich AK, Liu Y, Caligiuri MA.

Cancer Res. 2004 Nov 1;64(21):8062-7.


Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.

Gold JE, Zachary DT, Osband ME.

Clin Immunol Immunopathol. 1994 Oct;73(1):115-22. Erratum in: Clin Immunol Immunopathol 1995 Jul;76(1 Pt 1):105. Retraction in: Clin Immunol Immunopathol. 1998 Jun;87(3):314.


Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.

Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P, Radvanyi L.

PLoS One. 2013;8(4):e60031. doi: 10.1371/journal.pone.0060031. Epub 2013 Apr 1.

Supplemental Content

Support Center